Pheon Therapeutics
Updated: November 22, 2025
CEO Bertrand Damour
Country: UK | Funding: $188M (+)
Website: https://pheontx.com
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
Website: https://pheontx.com
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
